{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.3","upperLimit":"82.1","value":"75.2"},{"groupId":"OG001","lowerLimit":"52.7","upperLimit":"69.6","value":"61.3"},{"groupId":"OG002","lowerLimit":"60.8","upperLimit":"77.9","value":"70.3"},{"groupId":"OG003","lowerLimit":"61.6","upperLimit":"78.2","value":"70.8"}]}],"title":"24 Months (n=124,123,124, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.2","upperLimit":"72.9","value":"64.8"},{"groupId":"OG001","lowerLimit":"37.7","upperLimit":"56.5","value":"47.4"},{"groupId":"OG002","lowerLimit":"57.3","upperLimit":"75.1","value":"67.1"},{"groupId":"OG003","lowerLimit":"48.4","upperLimit":"66.8","value":"58.2"}]}],"title":"36 Months (n=124,123,124, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.0","upperLimit":"66.5","value":"57.8"},{"groupId":"OG001","lowerLimit":"30.6","upperLimit":"49.3","value":"40.0"},{"groupId":"OG002","lowerLimit":"53.7","upperLimit":"72.2","value":"63.8"},{"groupId":"OG003","lowerLimit":"45.2","upperLimit":"64.8","value":"55.1"}]}],"title":"48 Months (n=124,123,124, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.2","upperLimit":"59.3","value":"50.2"},{"groupId":"OG001","lowerLimit":"27.1","upperLimit":"45.8","value":"36.4"},{"groupId":"OG002","lowerLimit":"46.9","upperLimit":"66.5","value":"57.4"},{"groupId":"OG003","lowerLimit":"40.2","upperLimit":"59.4","value":"50.2"}]}],"title":"60 Months (n=124,123,124, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.0","upperLimit":"53.6","value":"44.0"},{"groupId":"OG001","lowerLimit":"22.4","upperLimit":"40.8","value":"31.4"},{"groupId":"OG002","lowerLimit":"40.0","upperLimit":"60.4","value":"50.7"},{"groupId":"OG003","lowerLimit":"35.2","upperLimit":"54.8","value":"45.3"}]}],"title":"72 Months (n=124,123,124, 127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"48.7","value":"39.0"},{"groupId":"OG001","lowerLimit":"21.2","upperLimit":"39.6","value":"30.2"},{"groupId":"OG002","lowerLimit":"31.5","upperLimit":"52.4","value":"42.1"},{"groupId":"OG003","lowerLimit":"31.3","upperLimit":"51.0","value":"41.3"}]}],"title":"84 Months (n=124,123,124, 127)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"124"},{"groupId":"OG003","value":"126"}],"units":"Participants"}],"description":"PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to \\> 20,000/mm\\^3 or an increase by \\> 50,000/mm\\^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-resistant participants were summarized.","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}